Veterinary Compounding for Myasthenia Gravis

Author(s):  Davidson Gigi S

Issue:  Sep/Oct 2008 - Veterinary Compounding
View All Articles in Issue

Abstract:  Myasthenia gravis is a neuromuscular disease commonly encountered in veterinary medicine. With accurate diagnosis, treatment, and compliant caregivers, the prognosis for remission and a normal life is good. Unfortunately, drugs used to diagnose and treat myasthenia gravis are frequently unavailable due to manufacturer shortages. During these periods, compounding pharmacists can play a valuable role in maintaining a good quality of life for these patients by providing compounded versions of drugs that are commercially unavailable.

Related Keywords: Gigi S. Davidson, BSPh, DIVCP, FSVHP, formulations, myasthenia gravis, muscle disorders, dogs, veterinary medicine, muscle weakness, cats, edrophomium hydrochloride, acetylcholinesterase inhibitor, acetycholine, neurotransmitter, anticholinesterase agents, pyridostigmine bromide, cellulose, methylcellulose, excipients

Related Categories: EXCIPIENTS, FORMULATIONS, VETERINARY, MUSCULOSKELETAL DISORDERS, NEUROLOGY

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=2820

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products